Towards an HBV cure: State-of-the-art and unresolved questions-report of the ANRS workshop on HBV cure
Journal
Gut
Journal Volume
64
Journal Issue
8
Pages
1314-1326
Date Issued
2015
Author(s)
Zeisel M.B.
Lucifora J.
Mason W.S.
Sureau C.
Beck J.
Levrero M.
Kann M.
Knolle P.A.
Benkirane M.
Durantel D.
Michel M.-L.
Autran B.
Cosset F.-L.
Strick-Marchand H.
Trépo C.
Carrat F.
Lacombe K.
Schinazi R.F.
Barré-Sinoussi F.
Delfraissy J.-F.
Zoulim F.
Abstract
HBV infection is a major cause of liver cirrhosis and hepatocellular carcinoma. Although HBV infection can be efficiently prevented by vaccination, and treatments are available, to date there is no reliable cure for the >240 million individuals that are chronically infected worldwide. Current treatments can only achieve viral suppression, and lifelong therapy is needed in the majority of infected persons. In the framework of the French National Agency for Research on AIDS and Viral Hepatitis 'HBV Cure' programme, a scientific workshop was held in Paris in June 2014 to define the state-ofthe- art and unanswered questions regarding HBV pathobiology, and to develop a concerted strategy towards an HBV cure. This review summarises our current understanding of HBV host-interactions leading to viral persistence, as well as the roadblocks to be overcome to ultimately address unmet medical needs in the treatment of chronic HBV infection.
SDGs
Other Subjects
alpha glucosidase inhibitor; antivirus agent; benzimidazole bm 601; complementary DNA; cyclosporin A; DNA vaccine; ezetimibe; hepatitis B surface antigen; hepatitis B vaccine; heteroaryldihydropyrimidine derivative; miglustat; myrcludex B; nitazoxanide; phenylpropenamide derivative; recombinant interferon; recombinant interleukin 7; recombinant lambda interferon; sulfonamide; thymosin alpha1; toll like receptor 7 agonist; toll like receptor agonist; triazol o pyrimidine derivative; unclassified drug; antivirus agent; virus DNA; adaptive immunity; antigen expression; Article; cellular immunity; chronic hepatitis B; DNA integration; drug targeting; Hepatitis B virus; human; incidence; infection rate; innate immunity; nonhuman; pathogenesis; persistent virus infection; phase 1 clinical trial (topic); phase 2 clinical trial (topic); phase 4 clinical trial (topic); prevalence; priority journal; seroconversion; virion; virus assembly; virus cell interaction; virus entry; virus replication; virus transformation; virus transmission; Carcinoma, Hepatocellular; complication; disease course; genetics; health; Hepatitis B, Chronic; liver cirrhosis; Liver Neoplasms; virology; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; DNA, Viral; Global Health; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Liver Cirrhosis; Liver Neoplasms
Publisher
BMJ Publishing Group
Type
journal article